Zhejiang Xianju PharmaceuticalLtd's (SZSE:002332) 16% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period

When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns.

Simply Wall StMay 21 02:24 ET

Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) Soars 25% But It's A Story Of Risk Vs Reward

Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) shareholders would be excited to see that the share price has had a great month, posting a 25% gain and recovering from prior weakness. Not all

Simply Wall StApr 26 20:02 ET

Xianju Pharmaceutical (002332.SZ): Net profit of 151 million yuan in the first quarter increased 13.53% year-on-year

Gelonghui, April 24, 丨 Xianju Pharmaceutical (002332.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,038 million yuan, up 8.42% year on year; net profit attributable to shareholders of listed companies was 151 million yuan, up 13.53% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 145 million yuan, up 9.83% year on year; basic earnings per share were 0.15 yuan.

Gelonghui FinanceApr 24 09:23 ET

Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

It is hard to get excited after looking at Zhejiang Xianju PharmaceuticalLtd's (SZSE:002332) recent performance, when its stock has declined 11% over the past three months. But if you pay close atte

Simply Wall StApr 15 20:35 ET

A Look At The Intrinsic Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Zhejiang Xianju PharmaceuticalLtd fair value estimate is CN¥9.79 With CN¥9.46 share price, Zhejiang Xianju PharmaceuticalLtd appears to be tr

Simply Wall StMar 23 20:14 ET

Xianju Pharmaceutical (002332.SZ): Plans to relinquish the priority subscription rights for Cuize Pharmaceutical's current capital increase

Gelonghui on March 7 丨 Xianju Pharmaceutical (002332.SZ) announced that Zhejiang Cuize Pharmaceutical Technology Co., Ltd. (“Cuize Pharmaceutical”) is a shareholding company of Zhejiang Xianju Pharmaceutical Co., Ltd., and the company holds 41.6501% of its shares. Recently, the company received a notice that Cuize Pharmaceutical plans to introduce investors to increase its registered capital. The registered capital is to be increased from 137.255.24 million yuan to 15.7019.53 million yuan, and the registered capital is 19.76.429 million yuan. The capital increase price is 36.43 yuan/share. Based on actual business conditions, the company plans to give up the priority of Cuize Pharmaceutical's current capital increase

Gelonghui FinanceMar 7 03:53 ET